Upexi (UPXI) Expected to Announce Earnings on Monday

Key Points

• Upexi (NASDAQ:UPXI) is set to announce its earnings on September 29th, with analysts predicting a loss of ($0.0650) per share and revenue of $4.0210 million for the quarter.
• Shares of Upexi recently fell by 14.0%, trading at $5.30, with a significant trading volume of over 7 million shares.
• Insider purchases have occurred recently, with Director Lawrence Dugan acquiring 11,000 shares at $5.69 each, indicating growing confidence in the company.

Upexi (NASDAQ:UPXI - Get Free Report) is expected to release its results before the market opens on Monday, September 29th. Analysts expect Upexi to post earnings of ($0.0650) per share and revenue of $4.0210 million for the quarter.

Upexi Stock Down 14.0%

Shares of Upexi stock traded down $0.87 during midday trading on Thursday, reaching $5.30. The company had a trading volume of 7,435,578 shares, compared to its average volume of 3,957,145. Upexi has a fifty-two week low of $1.90 and a fifty-two week high of $22.57. The stock has a fifty day moving average price of $6.50 and a 200 day moving average price of $6.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.37 and a quick ratio of 0.24.

Analyst Ratings Changes

UPXI has been the subject of a number of analyst reports. Wall Street Zen raised Upexi to a "hold" rating in a research report on Friday, May 30th. Cantor Fitzgerald upgraded Upexi to a "strong-buy" rating in a report on Wednesday, August 13th. Finally, Alliance Global Partners started coverage on Upexi in a report on Monday, August 4th. They issued a "buy" rating and a $15.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy" and a consensus price target of $15.50.

Insider Activity

In other news, Director Lawrence Dugan purchased 11,000 shares of Upexi stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average price of $5.69 per share, for a total transaction of $62,590.00. Following the transaction, the director owned 112,389 shares in the company, valued at $639,493.41. The trade was a 10.85% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gene Salkind acquired 20,243 shares of Upexi stock in a transaction that occurred on Friday, July 11th. The stock was acquired at an average cost of $4.94 per share, with a total value of $100,000.42. Following the purchase, the director owned 385,370 shares in the company, valued at $1,903,727.80. The trade was a 5.54% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 198,186 shares of company stock worth $997,759 over the last three months. Corporate insiders own 4.42% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Upexi stock. Geode Capital Management LLC purchased a new position in Upexi, Inc. (NASDAQ:UPXI - Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 335,953 shares of the company's stock, valued at approximately $1,002,000. Geode Capital Management LLC owned approximately 0.38% of Upexi at the end of the most recent quarter. 5.68% of the stock is currently owned by hedge funds and other institutional investors.

About Upexi

Upexi, Inc manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.